NOTICE OF MAILING CHANGE
☐ Check here if you wish to discontinue receiving this publication

NIH Guide: Distribution Center
National Institutes of Health
Room B3165B, Building 31
Bethesda, Maryland 20892

☐ Check here if your address has changed and you wish to continue receiving this publication. Make corrections below and mail this page to:

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

OFFICIAL BUSINESS
Penalty for Private Use, $500

The NIH Guide announces scientific initiatives and provides policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in extramural programs administered by the National Institutes of Health.
NOTICES

REVISED ANNOUNCEMENT: ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) RESEARCH CENTERS, MH-86-16 .................................................. 1
Alcohol, Drug Abuse, and Mental Health Administration
Index: ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH ADMINISTRATION

DATED ANNOUNCEMENTS (RFPs AND RFAs AVAILABLE)

AVAILABILITY OF THE ADAMHA FIRST AWARD ........................................ 1
Alcohol, Drug Abuse, and Mental Health Administration
Index: ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH ADMINISTRATION

BIOLOGICAL AND BIOPHYSICAL PROPERTIES OF HTLV-III/LAV AND RELATED RETROVIRUSES (RFA) .................................................. 2
National Institute of Allergy and Infectious Diseases
Index: ALLERGY AND INFECTIOUS DISEASES

IMMUNOPATHOGENESIS OF HTLV-III/LAV INFECTIONS (RFA) ....................... 3
National Institute of Allergy and Infectious Diseases
Index: ALLERGY AND INFECTIOUS DISEASES

COOPERATIVE AGREEMENTS FOR NATIONAL COOPERATIVE DRUG DISCOVERY GROUPS FOR LUNG CANCER (NCDDG/LUNG) (RFA) ........... 5
National Cancer Institute
Index: CANCER

COOPERATIVE AGREEMENTS FOR NATIONAL COOPERATIVE DRUG DISCOVERY GROUPS FOR COLON CANCER (NCDDG/-Colon) (RFA) ................. 5
National Cancer Institute
Index: CANCER

MECHANISM(S) OF OBESITY-ASSOCIATED HYPERTENSION (RFA) ..................... 6
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, AND BLOOD

ION CHANNELS IN PULMONARY CELLS ................................................... 6
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, AND BLOOD

A-1-PROTEASE INHIBITOR DEFICIENCY: VECTOR FOR GENE THERAPY (RFA) .......... 7
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, AND BLOOD

MENTAL RETARDATION RESEARCH CENTERS (P30) (RFA) ........................... 7
National Institute of Child Health and Human Development
Index: CHILD HEALTH AND HUMAN DEVELOPMENT

ONGOING PROGRAM ANNOUNCEMENTS

CARDIOVASCULAR STUDIES IN PARTICULAR ANIMAL MODELS ...................... 9
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, AND BLOOD

ERRATUM

REVISED COMPETING INDIVIDUAL NATIONAL RESEARCH SERVICE AWARD APPLICATION KIT ................................................................. 10
National Institutes of Health
Index: NATIONAL INSTITUTES OF HEALTH
NOTICES

REVISED ANNOUNCEMENT: ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) RESEARCH CENTERS, MH-86-16

P.T. 04; K.W. 0715120, 0715095, 0404009

Alcohol, Drug Abuse, and Mental Health Administration

The Alcohol, Drug Abuse, and Mental Health Administration has revised its announcement on Acquired Immunodeficiency Syndrome (AIDS) Research Centers, MH-86-16. The statement concerning a maximum amount of $500,000 (direct costs) per year has been eliminated. In addition, the award criteria now read as follows: quality of the proposed center as determined during the review process; availability of funds; program balance; geographic distribution; and emphasis on both mental health and drug abuse aspects.

The receipt and review schedule has been changed to the following:

Applications in response to this announcement should be submitted by November 1, 1986 or March 15, 1987 for funding consideration in Fiscal Year 1987.

<table>
<thead>
<tr>
<th>RECEIPT OF APPLICATIONS</th>
<th>INITIAL REVIEW</th>
<th>ADVISORY COUNCIL REVIEW</th>
<th>EARLIEST AWARD DATE</th>
</tr>
</thead>
</table>

In Fiscal Year 1987, the National Institute of Mental Health and the National Institute on Drug Abuse anticipate funding two-three research centers.

DATED ANNOUNCEMENTS (RFPs AND RFAs AVAILABLE)

AVAILABILITY OF THE ADAMHA FIRST AWARD

P.T. 34; K.W. 0710030, 0404000, 1014002

Alcohol, Drug Abuse, and Mental Health Administration

The Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA) is pleased to announce the availability of the First Independent Research Support and Transition (FIRST) Award. ADAMHA is replacing the New Investigator Research Award (NIRA) with the FIRST award. ADAMHA will phase out the NIRA award as presently funded awards terminate and will accept no new NIRA applications for review. The initial receipt date for ADAMHA FIRST applications will be November 1, 1986.

The purposes of this new grant mechanism are to: underwrite the first investigative efforts of a newly independent investigator; provide a sufficiently long period of support for the new investigator to have an opportunity to demonstrate creativity, productivity and further promise; and to help effect a transition toward the traditional types of research project support. FIRST awards will provide up to $350,000 for up to 5 years of support.

The ADAMHA FIRST award is basically the same as the NIH FIRST award; however, there are some minor differences. Therefore, applicants are encouraged to contact the program staff listed below to obtain copies of the FIRST announcement and to determine priorities within program areas. The mailing address for these individuals is 5600 Fishers Lane, Rockville, Maryland 20857.

National Institute on Alcohol Abuse and Alcoholism

Helen Chao, Ph.D.
Chief, Biomedical Research Branch
Division of Extramural Research
Room 14C-17
Telephone: (301) 43-4223
BIOLOGICAL AND BIOPHYSICAL PROPERTIES OF HTLV-III/LAV AND RELATED RETROVIRUSES

RFA AVAILABLE: 87-AI-01

P.T. 34; K.W. 1002045, 1013004, 1003002, 0790000

National Institute of Allergy and Infectious Diseases

Application Receipt Date: January 5, 1987

The National Institute of Allergy and Infectious Diseases (NIAID) invites applications for regular research grants to investigate the biological and biophysical characteristics of HTLV-III/LAV. Investigators may propose studies to investigate the biological, biophysical, biochemical or structural properties of this virus or any of its components. Proposals to focus on one or more of these areas of investigation are encouraged. Applications which involve other collaborating scientists or institutions are encouraged, but not required for response to this announcement. Included in the scope of this announcement is the study of the relationship between structure and function of any of the components of HTLV-III/LAV or related retroviruses.
BACKGROUND

The Acquired Immunodeficiency Syndrome (AIDS), a recent internationally recognized health problem, is characterized by a severe and persistent breakdown in the immune system.

OBJECTIVES AND SCOPE

The NIAID wishes to stimulate research on the biophysical and biochemical characteristics of HTLV-III/LAV and related retroviruses. Investigators are encouraged to consider projects to determine the three dimensional structure of envelope glycoproteins, reverse transcriptase, gag protein, or other viral components and to relate structural studies with biological, biochemical or biophysical processes. Studies to identify biological or biochemical mechanisms of viral penetration into susceptible host cells, release of viral particles from infected cells, regulation of biochemical events involved in the replication of these viruses or the regulation of the latent state are particularly encouraged. Collaboration with other investigators or institutions is encouraged, but not essential.

APPLICATION SUBMISSION AND REVIEW

Eligibility: Universities, medical colleges, hospitals, and laboratories of other public, private or for profit institutions are eligible.

Submission: To identify responses to this announcement, check "yes" and put "Biophysical Properties of HTLV-III/LAV and Related Retroviruses" under item 2 on page 1 of the grant application. Use the regular research grant application form PHS 398 that is available in business offices of most research institutions or from the Division of Research Grants (DRG), NIH. The completed original application and five (5) copies should be mailed to:

Division of Research Grants
NIH Westwood Building - Room 240
Bethesda, Maryland 20892

To expedite review a copy should also be mailed directly to:

Review Branch, Extramural Activities Programs, NIAID
Westwood Building - Room 710
Bethesda, Maryland 20892

MECHANISM OF SUPPORT

While the NIAID is expected to receive primary assignment on all applications, institute assignment of applications will follow established NIH guidelines. The NIAID expects to allocate $2.5 million to specifically fund applications in response to this RFA. The number of awards to be made is dependent upon receipt of a sufficient number of applications of high scientific merit and upon the availability of funds. The earliest possible award date is July 1, 1987. This RFA may be reissued.

INQUIRIES

Additional information and a copy of the complete RFA may be obtained from:

Chief, Pathogenesis Branch AIDS Program, NIAID, NIH
Westwood Building, Room 753
Bethesda, Maryland 20892
Telephone: (301) 496-0545

IMMUNOPATHOGENESIS OF HTLV-III/LAV INFECTIONS

RFA AVAILABLE: 87-AI-02
P.T. 34; K.W. 0710075, 0755020, 1002045

National Institute of Allergy and Infectious Diseases
Application Receipt Date: January 5, 1987

The National Institute of Allergy and Infectious Diseases (NIAID) invites applications for regular research grants to investigate the pathogenesis of infection by HTLV-III/LAV/HIV. These studies can explore any of the components of the immune system, cellular or humoral, as well as properties of the virus or host that are responsible for or contribute to pathologic processes encountered in this infection. Animal model systems may also be investigated.
BACKGROUND

The Acquired Immunodeficiency Syndrome (AIDS), a recent internationally recognized health problem, is characterized by a severe and persistent breakdown in the immune system. The central feature of this infection is that it is an infection of the immune system, specifically the T-helper cell. Accordingly, the infected host becomes susceptible to a variety of opportunistic infections and to various malignancies. Moreover, the virus has the capability to establish a latent state in the cells of the immune system. Many factors have been postulated that may play a role in the pathogenesis of this infection. These may include processes mediated by the virus itself, the immune system or other factors. It is important to understand the pathogenic processes in order to develop methods to control or prevent these effects.

OBJECTIVES AND SCOPE

The NIAID wishes to stimulate research in the pathogenesis of AIDS. As stated above, since this is an infection of the immune system it is likely that processes mediated by immunologic mechanisms are involved in the pathogenesis of this infection. In addition, the virus may have other important features that are important in the pathogenesis of this disease, such as neurotropism. Accordingly, the NIAID wishes to solicit regular research grant applications in this general area of pathogenesis to determine if other properties of the virus or of the host's response to infection can explain the pathologic processes that occur during or as a result of this infection.

APPLICATION SUBMISSION AND REVIEW

Eligibility: Universities, medical colleges, hospitals, and laboratories of other public, private or for profit institutions are eligible.

Submission: To identify responses to this announcement, check "yes" and put "Immunopathogenesis of HTLV-III/LAV Infections," under item 2 on page 1 of the grant application. Use the regular research grant application form PHS 398 that is available in business offices of most research institutions or from the Division of Research Grants (DRG), NIH. The completed original application and five (5) copies should be mailed to:

Division of Research Grants,
NIH Westwood Building - Room 240
Bethesda, Maryland 20892

To expedite review a copy should also be mailed directly to:

Review Branch, Extramural Activities Program, NIAID
Westwood Building - Room 710 B
Bethesda, Maryland 20892

MECHANISM OF SUPPORT

While the NIAID is expected to receive primary assignment on all applications, institute assignment of applications will follow established NIH guidelines. The NIAID expects to allocate $2.5 million to specifically fund applications in response to this RFA. The number of awards to be made is dependent upon receipt of a sufficient number of applications of high scientific merit and upon the availability of funds. The earliest possible award date is July 1, 1987. This RFA may be reissued.

INQUIRIES

Additional information and a copy of the complete RFA may be obtained from:

Chief, Pathogenesis Branch, AIDS Program, NIAID, NIH
Westwood Building - Room 753 B
Bethesda, Maryland 20892
Telephone: (301) 496-0545
COOPERATIVE AGREEMENTS FOR NATIONAL COOPERATIVE DRUG DISCOVERY GROUPS FOR LUNG CANCER (NCDDG/LUNG)

RFA AVAILABLE: 87-CA-01
P.T. 34; K.W. 0715035, 0715165, 0710100

COOPERATIVE AGREEMENTS FOR NATIONAL COOPERATIVE DRUG DISCOVERY GROUPS FOR COLON CANCER (NCDDG/COLON)

RFA AVAILABLE: 87-CA-02
P.T. 34; K.W. 0715, 0715085, 0710100

National Cancer Institute

Application Receipt Date: January 16, 1987

In 1983 and 1984 NCI requested applications for national Cooperative drug discovery groups (Vol. 12, No. 7, July 15, 1983, and Vol. 13, No. 9, August 3, 1984). These two RFAs represent expansion of this program to deal with specific cancer sites.

SUMMARY

Prior Requests for Applications resulted in funding of four National Cooperative Drug Discovery Groups for the discovery of new entities and strategies for cancer treatment. The two reissuances announced herein offer assistance to National Cooperative Drug Discovery Groups for the discovery of new therapies for lung cancer (NCDDG/LUNG) and for colorectal cancer (NCDDG/COLON), specifically.

The NCDDG/LUNG (RFA 87-CA-01) and NCDDG/COLON (RFA 87-CA-02) programs are designed to assist leading researchers in diverse scientific disciplines to interact as a unit, regardless of their individual institutional affiliations or prior direct involvement in cancer related research. The purpose is to mobilize, with NCI support, the outstanding talents required to exploit leads from fundamental studies and to extrapolate them to improved treatments for these high incidence malignancies. Each NCDDG/LUNG or NCDDG/COLON is envisioned as being composed of a Principal Investigator and a number of Program Leaders who will conduct interdependent and synergistic laboratory programs to conceptualize, create, and evaluate, preclinically, new therapies in accordance with the applicant's scientific goals and technical approaches to goal achievement. An NCDDG may be made up of scientists in academic, non-profit research, and commercial organizations.

Awards will be made as cooperative agreements. Assistance via cooperative agreement differs from the traditional research grant in that the cooperative agreement funding mechanism anticipates substantial NCI staff participation during performance. The role of NCI as a member of the Group is described in each RFA. Essentially, the extramural NCI staff concerned with the administration of grants and contracts will apply its experiences and appropriate resources to facilitate and stimulate the realization of Group objectives. The active participation of industry is encouraged, because it will allow this segment of the scientific community to contribute its considerable intellectual and material resources. The interaction of academic and research organizations with industry and Government will facilitate subsequent development (preferably through private venture capital, but alternatively, by Government) and marketing of new inventions.

NCI hopes to make multiple awards for project periods of five years and has set aside $2,000,000 for the initial year's funding of the NCDDG/LUNG program (87-CA-01) and $1,000,000 for the initial year's funding of the NCDDG/COLON program (87-CA-02).

Either or both Requests for Applications can be obtained from:

Dr. John M. Venditti
Program Director
National Cooperative Drug Discovery Groups
Landow Building, Room 5C08
Division of Cancer Treatment
National Cancer Institute
Bethesda, MD 20892
Telephone: (301) 496-8783

Prospective applicants are requested to specify the RFA(s) of interest by title and number.
MECHANISM(S) OF OBESITY-ASSOCIATED HYPERTENSION

RFA AVAILABLE: 87-HL-04-H

P.T. 34; K.W. 0715115, 0755030, 0715145

National Heart, Lung, and Blood Institute
Application Receipt Date: January 15, 1987

The Hypertension and Kidney Diseases Branch of the Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute (NHLBI) announces the availability of a Request for Applications (RFA) on the above subject. Awards will be made for a period up to five years.

Obesity is associated with hypertension and in some instances predisposes to its development. Research in the fields of obesity and hypertension suggests that there are a number of weight and blood pressure regulatory systems.

The intent of this RFA is to encourage research seeking to elucidate the underlying mechanism(s) of obesity-associated hypertension in the hope that a path to improved control or prevention may be disclosed. Although clinical research is not excluded, it is expected that proposals will emphasize basic science research.

This announcement may be of particular interest to investigators with expertise in numerous basic and clinical disciplines, ranging from physiology, cell biology, molecular biology, pharmacology, and biochemistry to clinical nutrition. Awards in response to this announcement will be made to foreign institutions only for research of very unusual merit, need, and promise, and in accordance with PHS policy governing such awards.

TIMETABLE
Letter of Intent December 1, 1986
Application Receipt Date January 15, 1987
Technical Review April 1987
Advisory Council Review May 1987
Award Date August 1987

INQUIRIES

Inquiries concerning this program and requests for copies of the RFA should be addressed to:

Mr. Armando Sandoval
Division of Heart and Vascular Diseases
National Heart, Lung, and Blood Institute
National Institutes of Health
Federal Building Room, 4C12
Bethesda, Maryland 20892
Telephone: (301) 496-1857

Release Date: October, 1986

ION CHANNELS IN PULMONARY CELLS

RFA AVAILABLE: 87-HL-02-L

P.T. 34; K.W. 1002004, 0765010, 0715165, 0710050, 1002008, 0710100

National Heart, Lung, and Blood Institute
Application Receipt Date: April 17, 1987

The Division of Lung Diseases invites grant applications for a single competition for support of research on ion channels in pulmonary cells.

The main purpose of this special grant program is to stimulate basic research directed at the isolation and characterization of selected ion channels from airway cells (epithelial, smooth muscle or others) and elucidation of the processes regulating their biosynthesis, function and turnover in health and their abnormal behavior in pulmonary disease. Among the disciplines and expertise that may be appropriate for this research program are lung cell biology, electrophysiology, and molecular biology, membrane chemistry, biochemistry, pharmacology, and pulmonary medicine.
A letter of intent is requested by January 15, 1987, and the deadline for receipt of applications is April 17, 1987. Awards in connection with this announcement will be made to foreign institutions only for research of very unusual merit, need, and promise, and in accordance with Public Health Service policy governing such awards.

Requests for copies of this RFA should be addressed to:

J. Sri Ram, Ph.D.
Chief, Airways Diseases Branch
Division of Lung Diseases, NHLBI
3333 Westbard Avenue, Room 6A15
Bethesda, Maryland 20892
Telephone: (301) 496-7332

A-1-PROTEASE INHIBITOR DEFICIENCY: VECTOR FOR GENE THERAPY

RFA AVAILABLE: 87-HL-03-L

P.T. 34; K.W. 1002008, 0710015, 1002045, 1002004, 1002034

National Heart, Lung, and Blood Institute
Application Receipt Date: April 17, 1987

The Division of Lung Diseases invites grant applications to support research aimed at developing a viral vector which could be useful for somatic gene therapy to correct the genetic deficiency for alpha-1-protease inhibitor (A-1-Pi).

The overall objective of this RFA is to encourage research towards developing a vector which would permit gene therapy for human A-1-Pi genetic deficiency. Applications are invited for innovative studies designed for developing a tissue tropic vector capable of in vivo delivery of the A-1-Pi gene into appropriate cells, such as hepatic cells, and for modifying the gene with appropriate regulatory elements for its optimal expression in the cells. Among the disciplines and expertise that may be appropriate for this research program are molecular biology, genetic engineering, molecular virology, cell biology and physiology.

A letter of intent is requested by January 16, 1987, and the deadline for receipt of applications is April 17, 1987. Awards in response to this announcement will be made to foreign institutions only for research of very unusual merit, need, and promise, and in accordance with Public Health Service policy governing such awards.

Request for copies of this RFA should be addressed to:

Zakir H. Bengali, Ph.D.
Airways Diseases Branch
Division of Lung Diseases, NHLBI
5333 Westbard Avenue, Room 6A15
Bethesda, Maryland 20892
Telephone: (301) 496-7332

MENTAL RETARDATION RESEARCH CENTERS (P30)

RFA AVAILABLE: HD-87-01

P.T. 04; K.W. 0715130, 0745055, 1002053, 0715135, 1002019, 0745020, 0785055, 0710105, 1007009, 0710100, 0755030, 0404000

National Institute of Child Health and Human Development
Application Receipt Date: May 15, 1987

The National Institute of Child Health and Human Development (NICHD), through the Mental Retardation and Developmental Disabilities (MRDD) Branch, Center for Research for Mothers and Children (CRMC), invites research center core grant applications (P30) as part of the Institute’s Mental Retardation Research Centers Program to develop new knowledge in the field of prevention, treatment, and amelioration of mental retardation and developmental disabilities. Three or four centers may be supported in response to this announcement.
The primary objective of the NICHD Mental Retardation Research Center (MRRC) Program is to provide support and facilities for a cohesive, interdisciplinary program of research and research training in mental retardation and related aspects of human development.

NICHD has supported MRRCs through the provision of core grants (P30) which facilitate program coordination and support central research core units. Funds for the research projects using these core units come from independent sources including Federal, State and private organizations. This announcement seeks applications from existing MRRCs and from other comparable institutions that meet the qualifications for a program of mental retardation research.

BACKGROUND

A major goal of the MRDD Branch's MRRC Program is to prevent and/or ameliorate mental retardation. The degree of impairment associated with mental retardation varies in relation to the cause. Moderate and more severe mental retardation often results from problems that produce profound alterations in brain development and/or function. Diminished intellectual and adaptive capacity can often be traced to defective genes, teratogenic agents, infections, nutritional deficits, accidents, diseases and other disorders causing brain damage. A larger proportion of cases of mental retardation is related to environmental conditions and disorders of unknown etiology. These complex problems require integrated, multidisciplinary approaches involving biomedical and behavioral sciences in a variety of settings.

The purpose of a Mental Retardation Research Center is to provide a research environment in which interdisciplinary collaboration among investigators who are working in areas of relevance to the prevention and amelioration of mental retardation is facilitated. Such research will cover a broad spectrum of scientific approaches ranging from laboratory research on fundamental processes of abnormal development to clinical and educational research in which persons with mental retardation are studied. It is thought that major solutions to the problems of mental retardation will be found as a result of multidisciplinary collaboration involving a variety of approaches in the Mental Retardation Research Centers. As a result of the administrative and scientific organization within a MRRC and across the network of MRRCs, opportunities for breakthroughs will be enhanced.

RESEARCH SCOPE

MRRC Core Grants are intended to bring together in a center a variety of disciplines to work on the common problems of mental retardation. Consequently, applications for Mental Retardation Center Core Grants (P30) should include investigators studying a range of topics in basic and clinical or applied research. Applicants are encouraged to include both biomedical and behavioral components from among the following topics:

1. Developmental neurobiological studies in MRDD.
2. Inborn errors of metabolism in MRDD.
4. Toxicology and physical environmental factors in the etiology, treatment and prevention of MRDD.
5. Developmental pharmacology and psychopharmacology.
6. Infectious diseases in the etiology, prevention and treatment of MRDD.
7. Diagnosis.
8. Perinatal problems associated with MRDD.
9. Psychobiological processes in MRDD.
10. Psychological processes in MRDD.
11. Early interventions for infants born at risk.
13. Family and community studies.
Language and communication of MRDD populations.

Behavior in residential and educational settings.

Socioecological processes.

Epidemiology of MRDD.

ELIGIBILITY

Any of the following organizations are eligible to apply: Non-profit organizations and institutions; State and local governments and their agencies; and authorized Federal institutions. As stated in the NICHD Centers Guidelines, the NICHD will not support more than one NICHD center (P30, P50) in a given department or specialty unit.

MECHANISM, SCOPE AND SCALE OF SUPPORT

Mental Retardation Research Center grants will be supported through the customary grant-in-aid mechanism. Review of applications and management of grants will be subject to applicable policies for NIH research center grants.

Awards will be made for a period of 5 years. To be eligible for award as an MRRC, the Center must provide core support for a minimum of 10 projects funded from non-university sources.

The total direct costs requested for the first year may not exceed $500,000 for new grants and not more than 106% of the level recommended for the previous budget period of a competing renewal grant. Budgets of applications for new and renewal support will be stringently reviewed within these guidelines.

ESTIMATED NUMBER OF AWARDS

This is the first of a series of annual announcements. Plans are to make three or four awards in fiscal year 1988.

WHERE COMPLETE RFA MAY BE OBTAINED

A complete Request for Applications entitled "Mental Retardation Research Centers (P30)" and guidelines concerning "NICHD Research Centers Programs-Center Core Grants(P30)" may be obtained from:

Dr. Peter Vietze
Head MRRC Program, CRMC, NICHD
Room 7C09, Landow Building
Bethesda, Maryland 20892
Telephone: (301) 496-1383

ONGOING PROGRAM ANNOUNCEMENTS

CARDIOVASCULAR STUDIES IN PARTICULAR ANIMAL MODELS

P.T. 34; K.W. 0715040, 0715115, 0755020, 0765020, 0710095, 0785050, 0710100, 0735015, 0765035, 0710030

National Heart, Lung, and Blood Institute

The National Heart, Lung, and Blood Institute announces its intent to award small grants for cardiovascular research studies of a small or pilot nature using the nonhuman primate resource colonies supported by the Division of Heart and Vascular Diseases (DHVVD). This is a reissuance of a similar announcement in December 1985.
The program objectives are:

1. To conduct research on factors involved in the pathogenesis of atherosclerosis or of hypertension in nonhuman primate models that delineate particular aspects of these disorders.

2. To study pediatric and developmental aspects of atherosclerosis or hypertension in such models.

An additional objective of the program is to allow investigators from institutions that have a need, but do not have the resources, to conduct cardiovascular studies in the nonhuman primate. This will be accomplished through the use of the resources, facilities, and collaborative opportunities available at the existing DHVD supported colonies.

It is hoped that these small or pilot studies will lead to more clearly defined, efficiently executed regular research grant applications using the nonhuman primate as a model for studies in such areas as metabolism, nutrition, genetics, pediatrics, behavior, instrumentation, pharmacology, pathology, lesion regression, endocrine systems, the central nervous system, electrolyte transport and the microcirculation, as well as other studies related to the pathophysiology of atherosclerosis and hypertension.

The award will provide a maximum of $50,000 (direct costs) over a period not to exceed two years for technical assistance, supplies, small equipment, shipping, subcontract costs (to include fee-for-service costs at the primate facilities) and travel required by the project. (It is anticipated that most of the grants in this program will not require the full two-year time frame or the maximum costs.)

Application Submission and Review

Application receipt dates are the regular receipt dates of February 1, June 1, and October 1. Applications will be reviewed by Study Section as assigned by the Division of Research Grants. Adherence is required to the Federal Animal Welfare Regulations and to Interagency Research Animal Committee Guidelines for the use of the nonhuman primate.

Inquiries

For inquiries and copies of a more detailed program description and application instructions please contact:

Nanci C. Parsons  
National Heart, Lung, and Blood Institute  
Federal Building - Room 4A08  
Bethesda, Maryland 20892  
Telephone: (301) 496-3271

The programs of the Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, are identified in the catalog of Federal Domestic Assistance, number 13.837. Awards will be made under the authority of the Public Health Service Act, Section 301 (42 USC 241) and administered under PHS grant policies and Federal regulations, most specifically 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372, or to review by a Health Systems Agency.

ERRATUM

REVISED COMPETING INDIVIDUAL NATIONAL RESEARCH SERVICE AWARD APPLICATION KIT

P.T. 22, 44; K.W. 0710030, 1014002

National Institutes of Health

The above referenced announcement in the June 27 issue of the Guide (Vol.15, No. 9) caused misunderstanding about eligibility for the Minority Access to Research Careers (MARC) predoctoral fellowship program. This program is for individuals formerly supported under the MARC Honors Undergraduate Research Training Grant Program. We apologize for this misunderstanding. The MARC item should be modified as follows:

MARC Honors Undergraduate Research Training Grant Predoctoral and Faculty Fellowship Award applications to be submitted from eligible minority institutions and Visiting Scientist Award applications to be submitted by scientists at majority institutions are available from the Director, MARC Program, National Institute of General Medical Sciences, National Institutes of Health, Westwood Building, Room 9A-18, Bethesda, Maryland 20892, Telephone: (301) 496-7941.